Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Videos

John Burke, MD
Videos
Analysis of Online Treatment Decision Tool Reveals Variation in FL Management Between Experts and Oncology HCPs
03/22/2022
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses...
03/22/2022
Journal of Clinical Pathways
John Strickler, MD
Videos
Real-World Treatment Patterns Among Patients With HER2-Amplified Metastatic Colorectal Cancer
03/17/2022
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses...
03/17/2022
Journal of Clinical Pathways
Peter Riedell, MD
Videos
Real-World Safety, Efficacy, and Utilization of Axicabtagene Ciloleucel and Tisagenlecleucel for B-Cell Lymphomas
01/21/2022
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses...
01/21/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
Survey Assesses Community Oncologists/Hematologists’ Perceptions of Gene Therapy for Hematological Disorders
01/21/2022
Ajeet Gajra, MD, FACS, discusses survey results analyzing community oncologists/hematologists’ perceptions of gene therapies and barriers to adoption or integration into clinical practice.
Ajeet Gajra, MD, FACS, discusses survey results analyzing community oncologists/hematologists’ perceptions of gene therapies and barriers to adoption or integration into clinical practice.
Ajeet Gajra, MD, FACS, discusses...
01/21/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Atish Choudhury, MD, PhD, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Genetically Unselected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss treatment modalities that have demonstrated survival benefit in metastatic castration-resistant prostate cancer for genetically unselected patients.
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss treatment modalities that have demonstrated survival benefit in metastatic castration-resistant prostate cancer for genetically unselected patients.
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
MIchele Muir, PharmD
Videos
Real-World Effectiveness, Safety of Generic vs Branded Imatinib for CML
01/11/2022
Michele Muir, PharmD, discusses results from a study evaluating the effectiveness and safety of generic imatinib compared to branded imatinib for patients with CML in real-world clinical practice.
Michele Muir, PharmD, discusses results from a study evaluating the effectiveness and safety of generic imatinib compared to branded imatinib for patients with CML in real-world clinical practice.
Michele Muir, PharmD, discusses...
01/11/2022
Journal of Clinical Pathways
JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Popular Articles

Research in Review
PD-1 Expression in T-Cells Aids Immunotherapy Strategies for NSCLC
05/01/2017
JCP Editors
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early...
05/01/2017
Journal of Clinical Pathways
Research in Review
Novel Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer
04/11/2017
JCP Editors
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to research...
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to research...
A new...
04/11/2017
Journal of Clinical Pathways
Interview
The Potential Impact of Clinical Pathways for Bariatric Surgery
03/15/2017
JCP Editors
Obesity has reached a crisis point in the United States, and is now regularly classified as an epidemic.1 The proportion of obese adults now comprises one-third of the US population, according to data from the...
Obesity has reached a crisis point in the United States, and is now regularly classified as an epidemic.1 The proportion of obese adults now comprises one-third of the US population, according to data from the...
...
03/15/2017
Journal of Clinical Pathways
Research in Review
Genomic Profiling, Targeted Therapy Effectively Treats Histiocytic Disorders
02/17/2017
JCP Editors
Genomic profiling should be applied to patients with histiocytic disorders at diagnosis in order to guide targeted therapy, according to research published in the Journal of Clinical Investigation Insight (February...
Genomic profiling should be applied to patients with histiocytic disorders at diagnosis in order to guide targeted therapy, according to research published in the Journal of Clinical Investigation Insight (February...
...
02/17/2017
Journal of Clinical Pathways
Research in Review
Immune Checkpoint Inhibitor New Standard of Care for MSI-H Metastatic Colorectal Cancer
01/25/2017
JCP Editors
The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...
The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...
The...
01/25/2017
Journal of Clinical Pathways

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement